Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors

Add time:07/29/2019    Source:sciencedirect.com

Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family of enzymes, has been implicated to play a key role in the pathology of osteoarthritis. Recently, we have reported the discovery of a series of quinazoline-2-carboxamide based non-zinc-binding MMP-13 selective inhibitors, as exemplified by compound 1. We then continued our research of a novel class of zinc-binding inhibitors to obtain follow-up compounds with different physicochemical, pharmacokinetic, and biological activity profiles. In order to design selective MMP-13 inhibitors, we adopted a strategy of connecting a zinc-binding group with the quinazoline-2-carboxamide system, a unique S1′ binder, by an appropriate linker. Among synthesized compounds, a triazolone inhibitor 35 exhibited excellent potency (IC50 = 0.071 nM) and selectivity (greater than 170-fold) over other MMPs (MMP-1, 2, 3, 7, 8, 9, 10, 12, and 14) and tumor necrosis factor-α converting enzyme (TACE). In this article, the design, synthesis, and biological activity of novel zinc-binding MMP-13 inhibitors are described.

We also recommend Trading Suppliers and Manufacturers of 3-METHYL-4-METHYLENE-3,4-DIHYDROQUINAZOLINE-2(1H)-THIONE (cas 14333-74-5). Pls Click Website Link as below: cas 14333-74-5 suppliers

Prev:Oxidative esterification of aldehydes with alcohols using imidazolium perrhenate (cas 14333-24-5) catalysts
Next:The indium-catalysed hydration of alkynes using substoichiometric amounts of PTSA as additive)